Quick answer: NextGen's native Electronic Prior Authorization handles medication prior auths through Surescripts inside the chart, while AI prior authorization automation covers the medical and procedure authorizations — imaging, surgery, injectables — that run through payer portals and fax. Native ePA is the right tool for pharmacy PA tied to e-prescribing; AI automation adds the clinical-package assembly, submission, and status follow-up that native ePA doesn't do. Most NextGen practices run both and let each handle the workload it's built for.
What is NextGen's native Electronic Prior Authorization?
NextGen's native Electronic Prior Authorization (ePA) is a built-in feature that handles medication prior auths as part of e-prescribing. It runs on NextGen Communication Services and Surescripts, so when a provider prescribes a drug that needs authorization, the request can move electronically instead of by phone or fax.
It's a real capability and worth using. For a practice that writes a lot of prescriptions requiring prior auth — specialty drugs, controlled substances with step therapy, high-cost medications — native ePA cuts the back-and-forth for that specific slice of the work.
What it isn't: a general-purpose prior authorization engine. Native ePA is scoped to the pharmacy side. It doesn't assemble a clinical package for an imaging study, submit a surgical pre-cert through a payer portal, or chase a fax-only plan for a decision. That's by design — it was built for e-prescribing, not for the full spread of medical prior auths.
What is AI prior authorization automation?
AI prior authorization automation is software that completes the whole PA workflow — reading the chart, building the request, submitting it, and tracking the outcome — across the payers and channels that native ePA doesn't reach. Instead of a staffer copying clinical detail into a portal and checking back for days, an agent does the repetitive work and escalates only the cases that need judgment.
The scope is the key difference. Automation targets medical and procedure authorizations: imaging, surgeries, injectables, durable medical equipment, and the specialty procedures that generate the heaviest manual load. The AMA's 2024 prior authorization survey found practices average 39 requests per physician per week and 13 staff hours — most of that concentrated in exactly the medical PA work automation is built to absorb.
Platforms like Honey Health's Prior Authorization agent sit alongside NextGen for this. The agent pulls clinical evidence from the chart, assembles payer-specific requests, submits through portals or fax, tracks the decision, and writes it back — so the practice covers the workload native ePA leaves on the table.
Native ePA vs. AI automation: the core differences
The two tools solve different halves of the same problem. Here's how they compare across the dimensions that matter to an operator.
- Scope of authorizations. Native ePA: medication PA tied to e-prescribing. AI automation: medical and procedure PA — imaging, surgery, injectables, DME.
- Submission channels. Native ePA: electronic, through Surescripts. AI automation: payer portals, payer APIs, and fax — the channels the medical side still lives in.
- Human effort. Native ePA still relies on staff to initiate and manage requests. AI automation handles the rules-based majority end to end and routes only exceptions to a person.
- Clinical package assembly. Native ePA doesn't build the clinical justification for a medical procedure. AI automation does — pulling and organizing the supporting evidence a payer requires.
- Status follow-up. Native ePA surfaces medication ePA status. AI automation actively tracks medical PA status across payers and writes outcomes back to the chart.
The short version: native ePA is a channel for medication auths, while AI automation is a worker for medical auths. Comparing them head-to-head is a little like comparing an e-fax line to a full billing service — they overlap at the edges, but they're built for different jobs.
Where native ePA is the right tool
Reach for native ePA when the workload is pharmacy prior authorization. If your friction is prescriptions stalling because a drug needs payer sign-off, native ePA moves that request electronically and keeps it inside the e-prescribing flow your providers already use.
It also makes sense as table stakes. Because it's built into NextGen and runs on infrastructure you likely already have for e-prescribing, turning it on is a configuration task, not a new vendor relationship. There's little reason to leave medication ePA unused.
The honest limit: native ePA won't dent the medical PA backlog that usually drives staff burnout. If your billers are drowning in imaging and surgery authorizations, native ePA isn't the fix for that queue — it was never meant to be.
Where AI automation earns its place
AI automation earns its place on the medical and procedure PA volume that eats the most staff time. When your team is logging into five payer portals, faxing clinical packets, and calling to check status, that's the work an agent removes.
The economics back it up. The 2024 CAQH Index puts a manual prior authorization at about $3.41 per transaction versus $0.05 electronic, with roughly 14 minutes saved per transaction. Applied to medical PA volume — the bulk of the 39-per-physician-per-week figure — that's the difference between a stretched team and a functional one.
Automation also shrinks denial leakage. Roughly 15–25% of denials trace to eligibility and documentation issues that an agent catches before submission, which native ePA's medication scope doesn't address. The trade-off to be honest about: peer-to-peers and appeals still need a person, so automation handles the majority, not every case.
Why most NextGen practices end up running both
This isn't really an either/or. The practices that get the most out of NextGen turn on native ePA for medication auths and layer AI automation for the medical side. Each covers what the other can't.
Think of it as splitting the queue by type. Prescriptions that need authorization flow through Surescripts and native ePA. Imaging, procedures, injectables, and DME authorizations go to the agent, which assembles the package, submits, and follows up. Nothing falls through the gap between them.
Run together, the two give leadership something manual PA never did: visibility. Medication auths move electronically, medical auths move through the agent with tracked status written back to the chart, and the authorization queue stops being a black box spread across payer portals and staff sticky notes.
How to decide which one your practice needs first
If you're only going to stand up one at a time, let your PA mix decide the order. A quick way to think about it:
- Pull your prior auth volume by type. Look at a month of requests and split them into medication versus medical and procedure. Whichever bucket is bigger and more painful is where you start.
- If medication PA dominates, enable native ePA first. It's a configuration on infrastructure you likely already run for e-prescribing, so it's the fastest win and doesn't require a new vendor.
- If medical and procedure PA dominates — the more common case for specialty and multi-specialty groups — prioritize AI automation, because that's the volume driving your staff hours and your denial leakage.
- Weigh the burnout signal. If you have staff working prior auth exclusively, that's almost always the medical side. The AMA found 40% of practices dedicate staff to PA full-time, and automation is what gives those roles their time back.
- Check your denial reasons. If a meaningful share of denials trace to missing documentation or eligibility, automation's pre-submission checks address that directly; native ePA doesn't.
Most practices land on the same answer over time: turn on native ePA because it's nearly free to enable, and bring in automation for the medical PA backlog because that's where the hours and the money are. The sequence matters less than making sure neither half of your PA workload is left running on manual effort.
Frequently Asked Questions
Does AI automation replace NextGen's native ePA?
No. They cover different workloads. Native ePA handles medication prior auths through Surescripts; AI automation handles medical and procedure auths through portals and fax. Most practices run both, using each for the slice of the PA workload it was built for.
Can NextGen's native ePA handle imaging or surgery authorizations?
Not really. Native ePA is scoped to medication prior authorization tied to e-prescribing. Imaging, surgery, and injectable authorizations run through payer portals and fax, which is where AI automation comes in. Native ePA wasn't designed to assemble clinical packages for medical procedures.
Which saves more staff time, native ePA or AI automation?
It depends on your PA mix. Native ePA saves time on medication auths; AI automation saves time on the larger medical and procedure volume. Since medical PA drives most of the AMA's 39-requests-per-physician-per-week figure, automation usually reclaims more hours for practices with heavy procedure volume.
Is AI prior authorization automation secure enough for our data?
It should be. Any AI back-office vendor operating in healthcare needs to be HIPAA-compliant, BAA-ready, and ideally HITRUST-certified. Because automation reads and writes to the chart, ask any vendor to show their compliance posture before granting access. The same standard applies to any tool touching PHI.
Do we need to choose one before we start?
No. Native ePA is a configuration you can enable independently, and AI automation is a separate layer you can add on your own timeline. Many practices turn on native ePA first, then bring in automation for the medical PA backlog once they're ready to scale it.
